Showing results (41-50 of 57) with videos related to
Sort By:
Pageof 6
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 1, 2020
[Monitoring Tumor Infiltrating Lymphocytes by Peripheral Blood in Lung Cancer Patients]Satoshi Muto, Hikaru Yamaguchi, Hayato Mine, et al.Journal of Oncology|March 4, 2015
Prognostic Impact of Hypoxia-Inducible miRNA-210 in Patients with Lung AdenocarcinomaJun Osugi, Yuka Kimura, Yuki Owada, et al.International Journal of Clinical Oncology|July 1, 2026
Clinical utility of comprehensive genomic profiling in thoracic malignancies beyond conventional gene testingSatoshi Muto, Masaru Hisa, Jun Osugi, et al.British Journal of Cancer|November 26, 2019
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancerWungki Park, Laura Mezquita, Naoyuki Okabe, et al.Cancer Immunology, Immunotherapy : CII|October 1, 2021
The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective studyMitsuro Fukuhara, Satoshi Muto, Sho Inomata, et al.Anticancer Research|December 1, 2021
CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLCSatoshi Muto, Sho Inomata, Hikaru Yamaguchi, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 26, 2022
[Resistance Mechanisms to Immune Checkpoint Inhibitor and Its Overcome with Focus on β-Catenin in Lung Cancer]Satoshi Muto, Sho Inomata, Hikaru Yamaguchi, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 26, 2022
[β-Catenin Expression in Non-Small Cell Lung Cancer and Therapeutic Effect of Immune Checkpoint Inhibitors]Satoshi Muto, Sho Inomata, Hikaru Yamaguchi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 15, 2018
Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief ReportYuki Owada-Ozaki, Satoshi Muto, Hironori Takagi, et al.Cancer Immunology, Immunotherapy : CII|December 7, 2019
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancerYuki Ozaki, Satoshi Muto, Hironori Takagi, et al.Pageof 6